The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.
Katherine Y. Fan
No relevant relationships to disclose
Aaron Tyler Wild
No relevant relationships to disclose
Daniel A. Laheru
No relevant relationships to disclose
Timothy M. Pawlik
No relevant relationships to disclose
Lei Zheng
No relevant relationships to disclose
Dung Thi Le
No relevant relationships to disclose
Phuoc T. Tran
No relevant relationships to disclose
Avani Satish Dholakia
No relevant relationships to disclose
Rachit Kumar
No relevant relationships to disclose
Susannah G. Ellsworth
No relevant relationships to disclose
Amy Hacker-Prietz
No relevant relationships to disclose
Zeshaan Rasheed
No relevant relationships to disclose
Ana De Jesus-Acosta
No relevant relationships to disclose
Matthew Weiss
No relevant relationships to disclose
Martin Makary
No relevant relationships to disclose
John L. Cameron
No relevant relationships to disclose
Ralph H. Hruban
No relevant relationships to disclose
Elliott K. Fishman
No relevant relationships to disclose
Christopher Lee Wolfgang
No relevant relationships to disclose
Joseph M. Herman
No relevant relationships to disclose